Synthesis and Evaluation of Salicylanilide Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors
Authors:
- 2 September 2014
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 85 (3) , 280-289
Abstract
Two series of novel salicylanilide were synthesized as potential epidermal growth factor receptor (EGFR) inhibitors. The enzyme inhibitory activity against EGFR of all compounds was carried out, and their antiproliferative activities against the A549 and A431 cell lines were also evaluated. Of the compounds studied, majority of them exhibited high antiproliferative activities compared with gefitinib; especially, 12a and 12b exhibited stronger inhibitory activity against EGFR with IC50 values of 10.4 ± 2.25 and 15.4 ± 2.33 nm, respectively, which were comparable to the positive control of gefitinib (IC50 = 12.1 ± 2.21 nm). Compound 12b also showed outstanding inhibitory activity against A431 and A549 cell lines with the IC50 values of 0.42 ± 0.43 μm and 0.57 ± 0.43 μm, which was better than the positive controls. In the molecular modeling study, compound 12b was bound into the active pocket of EGFR with two hydrogen bond and with minimum binding free energy ▵Gb = −25.1125 kcal/mol. The result also suggested that compound 12b could bind the EGFR kinase well.Keywords
Funding Information
- National Drug Innovation Incubator Base Project (2012ZX09401006)
This publication has 16 references indexed in Scilit:
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845International Journal of Molecular Sciences, 2013
- In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound databaseJournal of Molecular Modeling, 2011
- Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinaseJournal of Enzyme Inhibition and Medicinal Chemistry, 2010
- Synthesis and biological evaluation of novel luteolin derivatives as antibacterial agentsEuropean Journal of Medicinal Chemistry, 2009
- Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinitiesBioorganic & Medicinal Chemistry Letters, 2006
- Acryloylamino-salicylanilides as EGFR PTK inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complicationsBioorganic & Medicinal Chemistry, 2004
- Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptorEuropean Journal of Medicinal Chemistry, 2004
- Signal transduction by receptors with tyrosine kinase activityCell, 1990